100K+ researchers trust BodyHackGuide. Join r/BodyHackGuide

Adalank

Nootropic PeptidePreclinical / Research compound

Also known as: Adamax-Selank, Adamax + Selank Hybrid, Ada-Lank

Adalank is a hybrid research peptide combining structural elements of Adamax (the adamantyl-modified Semax analog) and Selank (the anxiolytic Pro-Gly-Pro tuftsin analog). Vendors positioned it around 2022-2024 as a single-molecule replacement for users running parallel Adamax + Selank protocols — covering both cognitive enhancement and anxiolysis without two separate intranasal or subcutaneous regimens. Important naming caveat. "Adalank" is used by some vendors for the Adamax/Selank hybrid described here.

Half-Life: The commonly cited ~72-hour "functional duration" is an unverified community/vendor claim, not a measured value - no pharmacokinetic study of Adalank has ever been run. The figure is extrapolated from parent Adamax marketing claims. Actual serum half-life is unknown; there is no published PK data.Route: Intranasal, SubcutaneousMW: Molecular weight not established - Adalank is an undefined vendor construct with no verified value. As a rough estimate, a Semax-analog + Selank hybrid (the two named peptides plus an adamantyl group, minus water at the linkage) would fall around 1600-1900 Da depending on the linker and adamantyl chemistry. No vendor publishes a verified mass-spectrometry spectrum, and older "~935-1300 Da" figures are inconsistent with the stated sequence and should be disregarded.CAS: Not assigned (research peptide, no CAS registry entry as of 2026)

Last reviewed: Jun 1, 2026

Nootropic Peptide

Overview

At A Glance

Mechanism

Adamax component - BDNF and TrkB Pathway…

Half-Life

The commonly cited ~72-hour "functional duration" is an unverified community/vendor claim, not a measured value - no pharmacokinetic study of Adalank has ever been run. The figure is extrapolated from parent Adamax marketing claims. Actual serum half-life is unknown; there is no published PK data.

Dosing

Once or twice daily during cycles. Every-other-day protocols also documented.

Dose Range

200-1200 mcg per dose (intranasal or subcutaneous), 1-2x dailymcg

Routes

IntranasalSubcutaneous

Common Vials

5mgmg10mgmg

Potential Benefits

Combined cognitive enhancement and anxiolysis in one moleculeAdamax-tier BDNF / TrkB upregulation (inferred from constituent)Selank-tier GABAergic anxiolysis without sedation (inferred from constituent)Claimed sustained duration (~72 hours) used to justify every-other-day dosing - an unverified community/vendor claim, not measured pharmacokineticsImproved blood-brain-barrier penetration vs unmodified Selank or Semax (adamantane chemistry)Subjective "alert calm" - motivation without anxiety, focus without overstimulationNo reported benzodiazepine-like tolerance or withdrawal (inferred from Selank parent)

Safety Notes

Common

Mild headache (often dose-related and self-limiting)Transient insomnia if dosed in the eveningMild nasal irritation (intranasal route)Increased dream activitySubjective mood elevation (typically positive)

Mechanism of Action

Adamax component - BDNF and TrkB Pathway

The Adamax side of the molecule is hypothesized to upregulate brain-derived neurotrophic factor (BDNF) expression in the hippocampus and modulate TrkB receptor sensitivity. This is the proposed mechanism for the cognitive enhancement signal observed in community protocols - sustained focus, memory consolidation, and motivation.

Adamax component - D2 Receptor Modulation

Adamax also reportedly modulates dopamine D2 receptor sensitivity in ventral tegmental area / nucleus accumbens motivation circuits. This dopaminergic effect contributes to the "drive" and reward-system response some users report - distinct from but overlapping with stimulant-class effects.

Selank component - GABAergic Anxiolysis

The Selank moiety carries Selank's documented anxiolytic profile: GABAergic modulation without sedation, hippocampal BDNF upregulation (overlapping with the Adamax mechanism), and serotonergic/enkephalin-like effects. Selank does not produce benzodiazepine-like tolerance or withdrawal in published Russian outpatient trials - this is one of the central selling points of the family.

Selank component - Immune Modulation

Selank exhibits tuftsin-like activity: Selank's N-terminal Thr-Lys-Pro-Arg sequence IS tuftsin, a natural immunomodulatory tetrapeptide, and Selank is a synthetic analog built on that tuftsin core [PMID:31625062]. The C-terminal Pro-Gly-Pro is a synthetic stabilizing extension added to slow enzymatic breakdown - it is not derived from tuftsin. Through the tuftsin portion, Selank modulates cytokine balance and produces mild immune-support effects. Whether this carries over to the hybrid Adalank molecule depends on the specific bond chemistry used by the vendor - confirm with the supplier.

Combined effect profile

Users report an "alert calm" subjective state - Adamax-driven motivation and cognitive clarity layered onto Selank-driven anxiolysis. This is similar to running NA-Semax + Selank or P-21 + Selank stacks, but consolidated into one molecule with (claimed) extended half-life from the adamantane modification.

Blood-brain-barrier delivery

The adamantyl group inherited from the Adamax side is the same lipophilic cage structure used in amantadine and memantine to improve BBB permeability. This is hypothesized to lower the effective peripheral dose required to achieve central effects - though no direct PK comparison vs Adamax or Selank alone has been published.

Receptor binding duration

The ~72-hour functional duration after a single dose is an unverified community/vendor claim - no pharmacokinetic study has measured it. It is extrapolated from the parent Adamax marketing claims and used to justify every-other-day dosing schedules, but it should be treated as anecdote, not measured PK.

Overview

Adalank is a hybrid research peptide combining structural elements of Adamax (the adamantyl-modified Semax analog) and Selank (the anxiolytic Pro-Gly-Pro tuftsin analog). Vendors positioned it around 2022-2024 as a single-molecule replacement for users running parallel Adamax + Selank protocols — covering both cognitive enhancement and anxiolysis without two separate intranasal or subcutaneous regimens.

Important naming caveat. "Adalank" is used by some vendors for the Adamax/Selank hybrid described here. Other vendors use the same name for N-acetyl-Selank-amidate (Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2, ~792.9 Da) — a different compound that is just Selank with acetyl + amide stability caps and no adamantane modification. If you're sourcing Adalank, confirm with the vendor which interpretation their product matches, because the dosing, half-life, and mechanism differ meaningfully between the two.

Evidence base. Peer-reviewed literature for Adalank specifically — under either interpretation — is essentially nonexistent. PubMed returns zero hits for "Adalank" as of 2026. All pharmacological claims are extrapolated from the constituent compounds: Semax (~12 published studies, mostly Russian), Selank (~88 published studies including formal anxiolytic trials), Adamax (zero direct publications), and the broader adamantane-CNS modification literature (amantadine, memantine).

Where it sits. Treat Adalank as a vendor-formulated convenience peptide — Adamax-tier cognitive effects layered onto Selank-tier anxiolytic effects, with no direct head-to-head data versus running the two compounds separately. The hybrid is not a clinical drug, has no FDA or regulatory approval anywhere, and exists primarily as a research peptide sold by a handful of Western vendors (Limitless Life Nootropics, BioLongevity Labs, Olympic Peptide, Pure Lab Peptides). Researchers should approach claims of "30-100x more potent than Selank/Semax" found on vendor sites as vendor-marketing only — there is no published comparison to substantiate the potency multipliers.

Potential Research Fields

Cognitive enhancementAnxiolysisBDNF researchDopaminergic modulationHybrid peptide engineeringNootropic peptides

Chemical Information

IUPAC Name

No standardized IUPAC name. Hybrid construct combining N-acetyl-Met-Glu-His-Phe-Pro-Gly-Pro-Ala-Gly-amide (adamantyl-modified) with Thr-Lys-Pro-Arg-Pro-Gly-Pro.

CAS Number

Not assigned (research peptide, no CAS registry entry as of 2026)

Molecular Formula

Approximately C58H86N18O14 (calculated from hybrid construct; exact formula depends on linker chemistry)

Molecular Mass

Not established by mass spectrometry. A Semax-analog + Selank hybrid (adamantyl-modified) would be roughly 1600-1900 Da by summing the constituent peptides minus water at the linkage, but no vendor publishes a verified MS spectrum, so treat any single figure as unconfirmed. The previously listed "~1268 g/mol" value is inconsistent with the stated sequence.

Amino Acid Sequence

Hybrid: Adamax (Ac-MEHFPGPAG-NH2, adamantyl-modified) linked to Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) backbone. Exact bond chemistry varies by vendor — confirm with supplier.

Dosing & Protocols

Dosing Summary

Dose

200-1200 mcg per dose (intranasal or subcutaneous), 1-2x daily

Route

Intranasal or subcutaneous

Frequency

Once or twice daily during cycles. Every-other-day protocols also documented.

Duration

21-30 day cycles, with 7-14 day washouts between cycles. Avoid chronic continuous dosing.

Titration Schedule

Step	Weeks	Dose	Purpose
Week 1	—	200-400 mcg/day	Assess tolerance, baseline subjective shift
Weeks 2-3	—	400-800 mcg/day	Therapeutic dosing, peak subjective effects
Weeks 4 (advanced)	—	800-1200 mcg/day	Optimization for non-responders; not required for most users
Washout	—	0	Receptor resensitization, avoid chronic tolerance

Reconstitution Guide

Solvent

bacteriostatic water

Volume

2 mL

Storage

Refrigerate (2-8°C)

Stability

Up to 30 days refrigerated

Common Vial Sizes

5mg10mg

Instructions

Clean the vial stopper with an alcohol swab

Draw 2 mL bacteriostatic water into a syringe

Insert needle into vial and slowly inject solvent down the side wall

Gently swirl (never shake) until fully dissolved

Store refrigerate (2-8°c) after reconstitution

Important

• Never shake — gently swirl to preserve peptide bonds
• Use bacteriostatic water for multi-dose vials
• Discard if solution appears cloudy or discolored

Unlock Dosing Protocols

Free account gets you:

View beginner, intermediate & advanced protocols
See weight-based dosing calculations
Access cycle length & frequency data

Create free account Sign in

2,800+ researchers already in

Research

PubMed ResultsLast updated: June 1, 2026

Key Research Findings

No completed clinical trials for Adalank exist.

PubMed search for "Adalank" returns zero results as of 2026. ClinicalTrials.gov contains no registered trials. The compound exists outside any formal clinical development pipeline.

Evidence by proxy:

Adamax component: zero direct studies; effects inferred from Semax literature and adamantane-CNS modification literature (amantadine, memantine pharmacology)
Selank component: ~88 PubMed entries on parent Selank, including: — Russian outpatient anxiolytic trial vs medazepam
Multiple animal model studies of stress-resilience and BDNF modulation
Russian regulatory approval as anxiolytic in 2009 (Selemax / Selank brand)
P-21 / N-acetyl-Semax-amidate (related family compound): limited published Western studies; mostly Russian institute work on the parent Semax

What this means for researchers:

Treat Adalank as a vendor-formulated convenience product with pharmacology inferred entirely from constituent compounds. Do not cite "Adalank studies" — there are none. When publishing or sharing research findings using Adalank, the appropriate framing is Adamax + Selank hybrid and the appropriate citation set is the Semax + Selank + adamantane-CNS literature.

Notable absence:

No head-to-head efficacy or pharmacokinetic comparison vs Adamax + Selank co-administered separately. The "convenience advantage" is plausible but unverified. The "extended duration" claim is plausible (the adamantyl group on the Adamax half-shoulders the half-life extension) but unverified by independent measurement.

Vendor claims to discount:

"30-100x more potent than Selank or Semax" — no published source. Treat as vendor-marketing.
"Better BBB penetration than Adamax or Selank alone" — plausible based on adamantane chemistry but not directly measured.
"Clinically proven anxiolysis" — false. No clinical proof exists for Adalank itself; Selank parent has Russian regulatory approval but Adalank does not.

Safety & Side Effects

Reported (anecdotal, no formal trials):

Headache — most commonly reported side effect, typically dose-related and self-limiting within 1-3 days. More common with intranasal route at higher doses.
Transient insomnia — if dosed in the evening. Restrict to morning / early afternoon if sleep is sensitive.
Nasal irritation — intranasal route only. Usually resolves within the first week of use or with dilution to a lower per-spray concentration.
Mild mood elevation / irritability — typically positive but can tip into restlessness at higher doses or in users sensitive to dopaminergic stimulation.
Mild BP elevation — anecdotal. Monitor if you have baseline hypertension.
Increased dream activity — common with Selank-family compounds and reported with Adalank as well. Usually benign.

No reported serious adverse events in publicly available community datasets — but this is not a formal safety conclusion. The absence of SAEs reflects unregulated underreporting, not formal safety clearance.

No long-term safety data exists. Multi-month or multi-year exposure consequences are entirely uncharacterized. Cycling protocols (21-30 days on, 7-14 days off) are a precautionary mitigation, not a validated safe-use pattern.

If side effects emerge:

Headache or insomnia: lower dose by 50%, restrict to morning dosing
Mood instability or anxiety: discontinue immediately and consult a clinician
Persistent nasal irritation: switch to subcutaneous route or discontinue
BP elevation: discontinue and monitor

Reporting: Adalank does not appear in FDA MedWatch or any major adverse event database. Community reporting via Reddit (r/Nootropics, r/Peptides) is the de facto safety signal but is heavily biased by self-selection.

Unlock Research Data

Free account gets you:

Browse PubMed study summaries
See clinical trial phases & results
Access mechanism of action details

Create free account Sign in

2,800+ researchers already in

Interactions

Interaction Matrix

Contraindications

Absolute:

Pregnancy and lactation — no safety data, multi-mechanism profile creates compounded unknowns
Active psychiatric instability (acute mania, psychosis) — dopaminergic component may exacerbate
Pediatric use — not characterized in any age group below adult
Known hypersensitivity to peptide injections or any constituent peptide

Relative (caution):

Bipolar disorder (any phase) — dopaminergic D2 modulation may destabilize mood cycling
Uncontrolled hypertension — community reports of mild BP elevation at higher doses
Concurrent benzodiazepines or other GABAergic sedatives — additive effects on alertness
Concurrent MAOI therapy — theoretical interaction via dopaminergic component
Recent head trauma — no data; precautionary
Sleep disorders — late-day dosing can worsen insomnia; restrict dosing to before noon if sleep is fragile

Substance interactions to avoid:

Stimulants (amphetamines, methylphenidate) — additive dopaminergic load
Recreational dopaminergic compounds — same concern

Stack overlaps to avoid:

Semax, Selank, Adamax, P-21 at full simultaneous doses — Adalank already contains the Adamax + Selank pharmacophores

Research Disclaimer

This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.

No listings found for Adalank.

Get Adalank Price Drop Alerts

Set a target price and we'll notify you when any vendor drops below it.

Sign in to leave a review

Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with Adalank.

Related Compounds

View All

Adamax

Nootropic PeptidePreclinical / Research compound

Adamax is a synthetic nonapeptide (Ac-MEHFPGPAG-NH2) classified as a designer analog of Semax.

t½ No pharmacokinetic data. Community reports describe a subjectively long duration of effect (~2-3 days), supporting every-other-day or 3x/week dosing; serum half-life not characterized. 500-2000 mcg subcutaneous (community research dosing)

PreclinicalView Profile

Cerebrolysin

Nootropic PeptideClinical

Cerebrolysin is a porcine brain-derived peptide complex developed by EVER Neuro Pharma (Austria) — a low-molecular-weight neurotrophic preparation containing a mixture of free amino acids and bioactive peptides extracted from purified pig brain proteins.

t½ ~2-4 hours (multi-component peptide mix)

85 PubMedView Profile

Cortexin

Nootropic PeptideMarketed in Russia/CIS (Geropharm); human clinical use with limited-quality evidence (small, mostly Russian-language studies; no Western RCT; not FDA/EMA approved)

Cortexin is a purified peptide preparation extracted from cattle and pig cerebral cortex tissue — a low-molecular-weight neuropeptide complex used clinically in Russia and Eastern Europe for cognitive impairment, post-stroke recovery, encephalopathy, attention disorders, and pediatric developmental conditions. Like Cerebrolysin, Cortexin is positioned as a broad-spectrum neurotrophic preparation supplying bioactive peptides that mimic endogenous neurotrophic factors.

t½ ~2-3 hours (estimated from analog peptide preparations)

18 PubMedView Profile

NA-Semax

Nootropic PeptidePreclinical

NA-Semax is the N-acetyl-l-aspartyl variant of Semax — the original ACTH(4-7) Pro-Gly-Pro analog developed at the Russian Academy of Sciences in the 1990s.

t½ ~20-30 minutes (intranasal, estimated from analog data)

3 PubMedView Profile

NA-Semax Amidate

Nootropic PeptidePreclinical

NA-Semax Amidate is the C-terminally amidated NA-Semax — the carboxylic acid at the peptide's C-terminus is replaced with an amide group (-NH2), which is reported to further extend metabolic half-life by resisting carboxypeptidase cleavage in addition to the aminopeptidase resistance the N-acetyl group already provides. The practical effect is a peptide with dosing-frequency use: where standard Semax often requires 3-4 daily doses to maintain effect, NA-Semax Amidate is reported (in vendor monographs and community usage) to maintain subjective effects on a 1-2x daily schedule.

t½ ~30-45 minutes (estimated, longer than standard Semax)

2 PubMedView Profile

P-21

Nootropic PeptidePreclinical

P-21 is a synthetic cyclic dipeptide — Cyclo(L-prolyl-glycine) — derived from the Selank/Semax C-terminal Pro-Gly-Pro motif.

t½ Not formally characterized in published work. P021 has only been studied in rodents (oral/dietary and subcutaneous dosing); no human pharmacokinetic data exist.

4 PubMedView Profile

View Full Dosage Guide →

Protocols, calculator & safety for Adalank

Research Score

0 PubMed results

Quality Indicators

Data Completeness

75%

Description

Mechanism of Action

Chemical Data

Dosing Protocols

Safety Profile

PubMed Results

Interactions

Vendor Listings

Quick Facts

Half-Life

Molecular Weight

Administration

Intranasal, Subcutaneous

CAS Number

Not assigned (research peptide, no CAS registry entry as of 2026)

Trial Phase

Preclinical / Research compound

Safety Profile

Common Side Effects

• Mild headache (often dose-related and self-limiting)
• Transient insomnia if dosed in the evening
• Mild nasal irritation (intranasal route)
• Increased dream activity
• Subjective mood elevation (typically positive)

Research Disclaimer

This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.

Frequently Asked Questions

What's the difference between Adalank and just running Adamax + Selank together?

Pharmacologically, the goal is the same - Adamax's cognitive / motivational effects layered onto Selank's anxiolytic effects. The hybrid molecule is sold on a convenience argument (one product, one protocol) and a claimed PK argument (the adamantyl group extends receptor binding versus two separate peptides). There is no head-to-head data published comparing the hybrid to co-administration of the parents. Treat the convenience as real and the PK advantage as plausible-but-unverified.

Why are there no PubMed studies for Adalank?

Adalank is a vendor-formulated research peptide, not a clinical drug. It was not developed in an academic pipeline. Its components (Adamax and Selank) have separate literature bases, but the hybrid itself has zero direct publications. Effects, dosing, and safety are inferred entirely from the constituent compounds and community protocols.

Is Adalank the same thing as N-acetyl-Selank-amidate?

Sometimes - vendors are inconsistent. Some sell 'Adalank' as the Adamax+Selank hybrid described in this entry. Others use the same name for N-acetyl-Selank-amidate (Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2), which is just Selank with acetyl + amide stability caps and no adamantane group. Confirm with the supplier which interpretation their product matches because the dosing, half-life, and mechanism differ.

Intranasal or subcutaneous?

Both are documented. Intranasal is more common for users who already use Selank or Semax that way. Subcutaneous is favored when the vendor's product is larger / more lipophilic and absorbs poorly through nasal mucosa. The choice doesn't dramatically change the effect profile - both routes reach central targets. Subcutaneous gives faster onset; intranasal gives more controlled dose titration.

How long does a cycle last and why washouts?

Typical cycle is 21-30 days on, 7-14 days off. The washout is precautionary - Adalank modulates both BDNF / TrkB / D2 (from the Adamax side) and GABA / serotonergic systems (from the Selank side). Continuous chronic stimulation of any single receptor system risks desensitization. Cycling avoids that risk and preserves response across multiple cycles. There is no formal data establishing the optimal cycle length - these are community-developed precautions.

Can Adalank be used long-term?

There is no long-term safety data - none. Multi-month and multi-year exposure consequences are uncharacterized. Cycling protocols are a precautionary mitigation, not validation of long-term safety. If used across multiple cycles, monitor for mood changes, sleep disruption, and any cardiovascular shifts.

What does Adalank feel like subjectively?

Most users report an 'alert calm' state - focused and motivated without the anxiety that often comes with stimulant-class compounds, and calm without the sedation that often comes with GABAergic compounds. Subjective effects build over 7-10 days. Peak is typically reported in weeks 2-3 of a cycle. Effects taper over 1-2 weeks following the last dose. The ~72-hour 'receptor binding window' often cited for Adalank is an unverified community/vendor claim with no pharmacokinetic data behind it - it is not a measured figure, so treat the taper timeline as anecdotal.

Research Tools

Peptide Calculator

Reconstitution & syringe units

Reconstitution Guide

How to mix, step by step

Nasal Spray Calc

mL per actuation

Half-Life Visualizer

Decay curves

Related Compounds

View All

Adamax

Nootropic PeptidePreclinical / Research compound

Adamax is a synthetic nonapeptide (Ac-MEHFPGPAG-NH2) classified as a designer analog of Semax.

PreclinicalView Profile

NA-Semax is the N-acetyl-l-aspartyl variant of Semax — the original ACTH(4-7) Pro-Gly-Pro analog developed at the Russian Academy of Sciences in the 1990s.

t½ ~20-30 minutes (intranasal, estimated from analog data)

3 PubMedView Profile